37.10

0.40% -0.1587

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $37.10, with a volume of 164.96K. It is down -0.40% in the last 24 hours and up +15.25% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$37.26

Open:

$37.16

24h Volume:

164.96K

Relative Volume:

0.20

Market Cap:

$2.15B

Revenue:

$899.11M

Net Income/Loss:

$145.62M

P/E Ratio:

14.94

EPS:

2.4829

Net Cash Flow:

$322.54M

1W Performance:

+5.01%

1M Performance:

+15.25%

6M Performance:

+0.98%

1Y Performance:

+15.39%

1-Day Range:

$36.59

$37.35

1-Week Range:

$35.17

$37.40

52-Week Range:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

293

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	37.11	2.11B	899.11M	145.62M	322.54M	2.4829
VRTX Vertex Pharmaceuticals Inc	528.26	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.63	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.39	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.74	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.28	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Jul 02, 2026

HRMY growth trends beyond Wakix could shape its next growth phase - MSN

Jul 02, 2026

Jun 30, 2026

Form 144 HARMONY BIOSCIENCES HOLDINGS For: 30 June By Investing.com - Investing.com South Africa

Jun 30, 2026

Sandip Kapadia reports sale activity (HRMY) via Form 144 totaling 50,000 - Stock Titan

Jun 30, 2026

HRMY Maintained by Deutsche Bank -- Price Target Raised to $36 - GuruFocus

Jun 30, 2026

Deutsche Bank Adjusts Price Target on Harmony Biosciences to $36 From $30, Maintains Hold Rating - marketscreener.com

Jun 30, 2026

Jun 29, 2026

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView

Jun 29, 2026

Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline - TradingView

Jun 29, 2026

HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase - Zacks Investment Research

Jun 29, 2026

Jun 27, 2026

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits

Jun 27, 2026

Form 144 HARMONY BIOSCIENCES HOLDINGS For: 26 June By Investing.com - Investing.com South Africa

Jun 27, 2026